FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Online Sample Promotions Downplay Risk Info: Study

[ Price : $8.95]

Researchers say that the number of drug company Web sites offering vouchers or coupons for free samples or discounted prescription...

FDA Orphan Status for BioMarin Drug

[ Price : $8.95]

FDA grants BioMarin Pharmaceutical an orphan drug designation for 3,4-diaminopyridine (3,4-DAP) amifampridine phosphate for treati...

FDA Refuse to File on EMD Serono NDA

[ Price : $8.95]

FDA issues EMD Serono a refuse-to-file letter on an NDA for cladribine tablets, indicated for treating relapsing forms of multiple...

Transcept and FDA Agree to Meet on Rejected Insomnia Drug

[ Price : $8.95]

Transcept Pharmaceuticals and FDA agree to meet 1/20/09 to discuss a Complete Response Letter on an NDA for Intermezzo (zolpidem t...

Consumers Dont Pay Attention to Risk Info: Study

[ Price : $8.95]

ORC Guideline says its latest research shows that many consumers dont pay attention to mandated risk information in TV and print d...

Woodcock Describes Pain Management Difficult Balance

[ Price : $8.95]

CDER director Janet Woodcock says that FDA is working with doctors, pharmacists, and others to strike a balance between access to ...

Patient Advocates Criticize Drug Company Data Mining

[ Price : $8.95]

The Chicago Tribune says that patient advocates and some doctors complain about prescription data mining practices.

FDA Wants More Telavancin Safety, Efficacy Data

[ Price : $8.95]

FDA asks Theravance to submit additional data and analyses for use in evaluating the safety and efficacy of its telavancin for tre...

Appeals Court Rules Against Generic Drug Makers

[ Price : $8.95]

A federal appeals court reverses a lower court decision, finding that state failure-to-warn claims against generic manufacturers o...

FDA Approves New Cymbalta Indication

[ Price : $8.95]

FDA approves Lillys Cymbalta for a new indication maintenance treatment of generalized anxiety disorder in adults.